$133 Million is the total value of Abingworth LLP's 11 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTLA | Sell | Portola | $31,953,000 | -3.7% | 1,240,912 | -0.0% | 24.08% | +27.3% |
| RNA | Prosensa | $28,957,000 | -29.4% | 6,213,924 | 0.0% | 21.82% | -6.6% | |
| SUPN | Supernus | $27,108,000 | +2.9% | 3,600,000 | 0.0% | 20.43% | +36.0% | |
| AMRN | Amarinspons adr | $15,851,000 | -69.0% | 8,087,486 | 0.0% | 11.94% | -59.0% | |
| CEMP | Cempra | $8,850,000 | +7.8% | 714,285 | 0.0% | 6.67% | +42.6% | |
| ZGNX | Zogenix | $8,010,000 | +85.4% | 2,335,218 | 0.0% | 6.04% | +145.2% | |
| OGXI | Oncogenex Pharma | $5,035,000 | -10.2% | 603,740 | 0.0% | 3.79% | +18.7% | |
| GWPH | GW Pharmaspons adr | $4,248,000 | +144.6% | 102,200 | 0.0% | 3.20% | +223.3% | |
| ANTH | Sell | Anthera | $1,340,000 | -23.7% | 437,994 | -0.0% | 1.01% | +0.9% |
| HPTX | Hyperion | $1,259,000 | -22.8% | 62,500 | 0.0% | 0.95% | +2.2% | |
| ZLCS | Sell | Zalicus | $87,000 | -84.6% | 78,966 | -83.3% | 0.07% | -79.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Abingworth Management LTD #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.